Structure Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-97.68	-89.62	-52.84	-43.77	-16.04
Depreciation & Amortization	1.44	0.93	0.62	0.27	0.02
Share-Based Compensation	8.4	8.19	2.51	1.49	0.57
Other Operating Activities	-5.42	1.01	2.06	6.1	1
Operating Cash Flow	-93.26	-79.49	-46.12	-32.16	-14.28
Capital Expenditures	-2.33	-2.17	-0.16	-1.21	-0.02
Change in Investments	-215.58	-266.18	-61.95	19.07	-21.13
Investing Cash Flow	-217.91	-268.34	-62.11	17.86	-21.15
Share Issuance / Repurchase	301.52	473.1	0.03	0.01	0
Other Financing Activities	-19.02	-21.57	28.99	103.24	25.84
Financing Cash Flow	282.51	451.53	29.01	103.25	25.84
Net Cash Flow	-28.66	103.7	-79.21	88.95	-9.59
Free Cash Flow	-95.59	-81.66	-46.28	-33.37	-14.3
Free Cash Flow Per Share	-2.05	-2.22	-14.48	-12.30	-6.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).